Given its ‘mild’ covalent warhead and low reactivity across proteome, we nominate MYF-03–69 as a viable lead for drug discovery for not only mesothelioma, but other YAP or TEAD-dependent cancers such as liver cancer, liposarcoma, and lung cancer. Here, YAP1 is linked to cancer.